Who are VIR-7831's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casirivimab and Imdevimab Drug Combination, Ad26.COV2.S vaccine, COMIRNATY intramuscular injection, COVID-19 mRNA vaccine, COVID-19 vaccination, AntiCov-220.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vir-7831.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

VIR-7831 — Competitive Intelligence Brief

VIR-7831 (VIR-7831) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Infectious Disease.

phase 3 SARS-CoV-2 spike protein Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

VIR-7831 (VIR-7831) — National Institute of Allergy and Infectious Diseases (NIAID). VIR-7831 is a monoclonal antibody that targets the SARS-CoV-2 spike protein.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
VIR-7831 TARGET	VIR-7831	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3		SARS-CoV-2 spike protein
Casirivimab and Imdevimab Drug Combination	Casirivimab and Imdevimab Drug Combination	Mansoura University Hospital	marketed	Monoclonal antibody combination (SARS-CoV-2 neutralizing antibodies)	SARS-CoV-2 spike protein receptor-binding domain
Ad26.COV2.S vaccine	Ad26.COV2.S vaccine	University Medical Center Groningen	marketed	viral vector vaccine	SARS-CoV-2 spike protein
COMIRNATY intramuscular injection	comirnaty-intramuscular-injection	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
COVID-19 mRNA vaccine	COVID-19 mRNA vaccine	Vaccine Company, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
COVID-19 vaccination	COVID-19 vaccination	University Medical Center Groningen	marketed	vaccine	SARS-CoV-2 spike protein
AntiCov-220	AntiCov-220	Nguyen Thi Trieu, MD	marketed	Monoclonal antibody	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VIR-7831 — Competitive Intelligence Brief. https://druglandscape.com/ci/vir-7831. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab